Atezolizumab
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Martin Nino, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Atezolizumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is FDA approved for the treatment of elected patients (see below) with locally advanced or metastatic urothelial carcinoma. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Atezolizumab is also indicated for the treatment of patients with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Atezolizumab.. Common adverse reactions include fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation (≥20%) in patients with locally advanced or metastatic urothelial carcinoma. Most common adverse reactions (≥ 20%) in patients with metastatic non-small cell lung cancer were fatigue, decreased appetite, dyspnea, cough, nausea, musculoskeletal pain, and constipation..
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications
- ======Locally Advanced or Metastatic Urothelial Carcinoma=====
Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- Have disease progression during or following platinum-containing chemotherapy
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
- ======Metastatic Non-Small Cell Lung Cancer======
Atezolizumab is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Atezolizumab.
Dosage
Off-Label Use and Dosage (Adult)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Atezolizumab FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Contraindications
There is limited information regarding Atezolizumab Contraindications in the drug label.
Warnings
There is limited information regarding Atezolizumab Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Atezolizumab Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Atezolizumab Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Atezolizumab Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Atezolizumab in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Atezolizumab in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Atezolizumab during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Atezolizumab in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Atezolizumab in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Atezolizumab in geriatric settings.
Gender
There is no FDA guidance on the use of Atezolizumab with respect to specific gender populations.
Race
There is no FDA guidance on the use of Atezolizumab with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Atezolizumab in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Atezolizumab in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Atezolizumab in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Atezolizumab in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Atezolizumab Administration in the drug label.
Monitoring
There is limited information regarding Atezolizumab Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Atezolizumab and IV administrations.
Overdosage
There is limited information regarding Atezolizumab overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Atezolizumab Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Atezolizumab Mechanism of Action in the drug label.
Structure
There is limited information regarding Atezolizumab Structure in the drug label.
Pharmacodynamics
There is limited information regarding Atezolizumab Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Atezolizumab Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Atezolizumab Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Atezolizumab Clinical Studies in the drug label.
How Supplied
There is limited information regarding Atezolizumab How Supplied in the drug label.
Storage
There is limited information regarding Atezolizumab Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Atezolizumab |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Atezolizumab |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Atezolizumab Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Atezolizumab interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Atezolizumab Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Atezolizumab Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.